The NuMedii team is comprised of experienced biotechnology executives with expertise in genomic medicine, Big Data, drug development and commercialization.
Gini Deshpande, Ph.D.
Founder and Chief Executive Officer
Gini has over ten years of experience incubating, developing, and commercializing life sciences technologies to enable scientific innovations to reach patients. As a consultant to startups, she has enabled two companies to raise their initial rounds of financing. At Affymetrix, she was responsible for strategic marketing for their Academic Research Business Unit, dealing with their largest customer segment. Prior to that, she was Director of an early-stage business unit at Children’s Hospital Boston, where she secured $2.5 M in grant funding and enabled prototype development for six medical device products. She has also managed broad, diverse IP portfolios and closed academic licensing deals worth over $10M. Gini has co-authored numerous papers on NuMedii’s core technology. She received her PhD in Biological Sciences from Purdue University and did post-doctoral work at Harvard Medical School.
Craig Webb, Ph.D.
Chief Scientific Officer
As one of the founding scientists at the Van Andel Research Institute in Michigan, Craig has spent the past 13 years building a translational research enterprise focused on the application of genomic technologies in medicine. In addition to establishing and maintaining a successful basic science laboratory focused on deciphering the molecular mechanisms of tumor metastasis and drug resistance, his work also focused on the early development of precision medicine clinical trials within the West Michigan community, in which cancer patients were treated on the basis of tumor molecular profiling. These efforts resulted in the formation of four new companies in areas of bioinformatics, molecular diagnostics and clinical trial coordination (TransMed Systems, Intervention Insights, The Center for Molecular Medicine and ClinXus). Craig has authored numerous papers and book chapters, is an inventor on several patents and has been an invited speaker at several conferences. He has a BSc in Biochemistry, a PhD in cell biology and has done post doctoral work in molecular oncology.
Chief Technology Officer
Dr. Siddiqui has an extensive background in bioinformatics and software engineering. Recently, he served as Vice President of Product Development at Natera where he built Natera’s product management and program management functions. Dr. Siddiqui drove important improvements to Natera’s NIPT diagnostic including its cloud strategy and laid the foundation for its foray into cfDNA diagnostics. Prior to that, he served as the director of bioinformatics at Life Technologies. For his work on bioinformatics methods and software for next generation sequencing, Dr. Siddiqui was awarded the Life Technology Inventor Award. He has also served as Vice President of Research for Sirius Genomics in Vancouver, BC. He spent several years at the Genome Sciences Centre (GSC), part of the BC Cancer Agency, as Bioinformatics Group Leader. While at the GSC, Dr. Siddiqui led the creation of an international public-private consortium to define standards for NGS data. He is an inventor on several patents, and has been an author on over 30 peer-reviewed publications some of which have been published in Science and Nature. He holds a doctorate in Bioinformatics from Oxford University, and an undergraduate in Physics with honors from Cambridge University.
Chief Financial Officer
Ms. Linda Ara serves as Consulting Chief Financial Officer for life science companies including: CyberHeart Inc., Kai Pharmaceuticals Inc., CardioVention Inc. and Targesome Inc. Ms. Ara served as Chief Financial Officer of Sorbent Therapeutics, Inc. until January 27, 2014. She served as an Acting Chief Financial Officer of NextWave Pharmaceuticals, Inc. from February 2010 to May 2011. Ms. Ara has been consulting as a Finance Executive for over 17 years, primarily in Silicon Valley life science companies. Prior to her consulting career, Ms. Ara served as the Chief Financial Officer for Power-Sonic Corp., where she led a leveraged buyout of a competitor. She began her career in commercial banking with Wells Fargo and Union Bank, where Ms. Ara specialized in relationship management, middle market lending, and international banking. Ms. Ara has a degree in American history from the University of California, Berkeley.